IL284680A - Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same - Google Patents
Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the sameInfo
- Publication number
- IL284680A IL284680A IL284680A IL28468021A IL284680A IL 284680 A IL284680 A IL 284680A IL 284680 A IL284680 A IL 284680A IL 28468021 A IL28468021 A IL 28468021A IL 284680 A IL284680 A IL 284680A
- Authority
- IL
- Israel
- Prior art keywords
- dioxopiperidin
- oxoisoindolin
- fluorobenzonitrile
- piperazin
- oxy
- Prior art date
Links
- YTINZZFBHWSAGL-NDEPHWFRSA-N cc-92480 Chemical compound O=C1NC(CC[C@@H]1N1C(C2=CC=CC(=C2C1)OCC1=CC=C(CN2CCN(CC2)C2=C(C=C(C#N)C=C2)F)C=C1)=O)=O YTINZZFBHWSAGL-NDEPHWFRSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962790342P | 2019-01-09 | 2019-01-09 | |
| PCT/US2020/012687 WO2020146463A1 (en) | 2019-01-09 | 2020-01-08 | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL284680A true IL284680A (en) | 2021-08-31 |
Family
ID=69467745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284680A IL284680A (en) | 2019-01-09 | 2021-07-07 | Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11370777B2 (sr) |
| EP (2) | EP4725553A2 (sr) |
| JP (1) | JP7483722B2 (sr) |
| KR (1) | KR102875111B1 (sr) |
| CN (3) | CN118324742A (sr) |
| AU (1) | AU2020206694B2 (sr) |
| BR (1) | BR112021013435A2 (sr) |
| CA (1) | CA3125756A1 (sr) |
| DK (1) | DK3908582T3 (sr) |
| EA (1) | EA202191620A1 (sr) |
| ES (1) | ES3059967T3 (sr) |
| FI (1) | FI3908582T3 (sr) |
| HR (1) | HRP20260065T1 (sr) |
| IL (1) | IL284680A (sr) |
| LT (1) | LT3908582T (sr) |
| MX (1) | MX2021008295A (sr) |
| PL (1) | PL3908582T3 (sr) |
| PT (1) | PT3908582T (sr) |
| RS (1) | RS67646B1 (sr) |
| SG (1) | SG11202107439XA (sr) |
| SI (1) | SI3908582T1 (sr) |
| SM (1) | SMT202600018T1 (sr) |
| WO (1) | WO2020146463A1 (sr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020206692B2 (en) * | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| US20230114674A1 (en) * | 2020-01-20 | 2023-04-13 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| EP4183781A4 (en) * | 2020-07-20 | 2024-01-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof |
| EP4347037A1 (en) | 2021-05-27 | 2024-04-10 | Celgene Corporation | Methods of treating multiple myeloma using combination therapy |
| US20250368620A1 (en) * | 2024-05-30 | 2025-12-04 | Celgene Corporation | ARNT Degrading Compounds and Uses Thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| EP2536706B1 (en) * | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP3399981B1 (en) | 2016-01-08 | 2023-08-02 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| TWI791552B (zh) | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| EA202092830A1 (ru) * | 2018-05-23 | 2021-04-08 | Селджин Корпорейшн | Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения |
| BR112020023756A2 (pt) * | 2018-05-23 | 2021-02-09 | Celgene Corporation | tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila |
-
2020
- 2020-01-08 RS RS20260055A patent/RS67646B1/sr unknown
- 2020-01-08 CA CA3125756A patent/CA3125756A1/en active Pending
- 2020-01-08 PL PL20703618.7T patent/PL3908582T3/pl unknown
- 2020-01-08 LT LTEPPCT/US2020/012687T patent/LT3908582T/lt unknown
- 2020-01-08 CN CN202410399193.6A patent/CN118324742A/zh active Pending
- 2020-01-08 EP EP25213779.9A patent/EP4725553A2/en active Pending
- 2020-01-08 FI FIEP20703618.7T patent/FI3908582T3/fi active
- 2020-01-08 HR HRP20260065TT patent/HRP20260065T1/hr unknown
- 2020-01-08 DK DK20703618.7T patent/DK3908582T3/da active
- 2020-01-08 WO PCT/US2020/012687 patent/WO2020146463A1/en not_active Ceased
- 2020-01-08 PT PT207036187T patent/PT3908582T/pt unknown
- 2020-01-08 US US16/737,739 patent/US11370777B2/en active Active
- 2020-01-08 ES ES20703618T patent/ES3059967T3/es active Active
- 2020-01-08 EA EA202191620A patent/EA202191620A1/ru unknown
- 2020-01-08 CN CN202080019069.2A patent/CN113597425A/zh active Pending
- 2020-01-08 AU AU2020206694A patent/AU2020206694B2/en active Active
- 2020-01-08 SI SI202030713T patent/SI3908582T1/sl unknown
- 2020-01-08 EP EP20703618.7A patent/EP3908582B1/en active Active
- 2020-01-08 CN CN202210010514.XA patent/CN114394954B/zh active Active
- 2020-01-08 SG SG11202107439XA patent/SG11202107439XA/en unknown
- 2020-01-08 BR BR112021013435-2A patent/BR112021013435A2/pt not_active Application Discontinuation
- 2020-01-08 KR KR1020217025072A patent/KR102875111B1/ko active Active
- 2020-01-08 SM SM20260018T patent/SMT202600018T1/it unknown
- 2020-01-08 MX MX2021008295A patent/MX2021008295A/es unknown
- 2020-01-08 JP JP2021540023A patent/JP7483722B2/ja active Active
-
2021
- 2021-07-07 IL IL284680A patent/IL284680A/en unknown
-
2022
- 2022-05-27 US US17/827,491 patent/US12391672B2/en active Active
-
2025
- 2025-07-16 US US19/271,096 patent/US20250340536A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284680A (en) | Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same | |
| IL278854A (en) | Treatment of multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazine-1 -yl-3-fluorobenzonitrile | |
| SA520411007B1 (ar) | مركبات مضادة للتكاثر وطرق لاستخدامها | |
| PH12019501068A1 (en) | Crystalline forms of a magl inhibitor | |
| PL3644999T3 (pl) | Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu | |
| SA515360022B1 (ar) | أملاح وصور صلبة من المركب (s) ــ 3 ــ(4 ــ((4ــ(مورفولينو ميثيل)بنزيل)أوكسي)-1-أوكسو أيزو إندولين-2-يل)ببريدين-2 ،6-دايون، وتركيبات تشتمل عليها، وطرق استخدامها | |
| IL284665A (en) | Pharmaceutical compounds consisting of (S)-4- (4- (4- (((2- (2,6-dioxopyridin-3-yl)-1-oxoisoinolin-4-yl)oxy)methyl)benzyl)piperazine-1- YL)-3-fluorobenzonitrile and methods of using the same | |
| EP3735243A4 (en) | ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE | |
| IL292258A (en) | Pharmaceutical preparations comprising (s)-2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 3, discussion and methods of using them | |
| LT4178548T (lt) | Farmacinė kompozicija, apimanti (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il) -1-oksoizoindolin-4-il)oksi)metil)benzil)piperazin-1-il)-3-fluorbenzonitrilą, ir jos panaudojimo būdai | |
| HK40064284A (en) | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same | |
| HK40051930A (en) | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile | |
| HK40077320A (en) | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use | |
| HK40079627A (en) | Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same | |
| MX377657B (es) | "composicion farmaceutica que contiene un derivado de imidazolina" |